{"id":{"repo_id":"wfu","oai_identifier":"oai:wakespace.lib.wfu.edu:10339/82160"},"canonical_url":"https://search.dev.ndltd.org/etd/wfu/oai:wakespace.lib.wfu.edu:10339/82160","repository":{"repo_id":"wfu","name":"Wake Forest University","base_url":"https://wakespace.lib.wfu.edu/oai/request"},"display":{"title":"INVESTIGATION OF THE GENETIC ARCHITECTURE OF CARDIOMETABOLIC DISEASE","abstract":"Cardiometabolic syndrome (CMS) is a clustering of interrelated risk factors (central obesity, hyperglycemia, hypertension, insulin resistance, and dyslipoproteinemia) that promotes the development of atherosclerotic vascular disease and type 2 diabetes. It was recognized as a disease entity by the American Society of Endocrinology, National Cholesterol Education Program (NCEP), and World Health Organization in 2003 (Castro, El-Atat, McFarlane, Aneja, & Sowers, 2003). Previous genetic studies with monozygotic and dizygotic twin pairs suggested a strongly heritable pattern for CMS risk factors, i.e. it is estimated that circulating lipid heritability ranges from 0.58 to 0.66 (h2HDL=0.61, h2LDL=0.59, h2TC=0.58, h2TG=0.66) (Knoblauch et al., 1997). However, the exact genetic mechanism of the disease is poorly understood.","abstract_html":"Cardiometabolic syndrome (CMS) is a clustering of interrelated risk factors (central obesity, hyperglycemia, hypertension, insulin resistance, and dyslipoproteinemia) that promotes the development of atherosclerotic vascular disease and type 2 diabetes. It was recognized as a disease entity by the American Society of Endocrinology, National Cholesterol Education Program (NCEP), and World Health Organization in 2003 (Castro, El-Atat, McFarlane, Aneja, & Sowers, 2003). Previous genetic studies with monozygotic and dizygotic twin pairs suggested a strongly heritable pattern for CMS risk factors, i.e. it is estimated that circulating lipid heritability ranges from 0.58 to 0.66 (h2HDL=0.61, h2LDL=0.59, h2TC=0.58, h2TG=0.66) (Knoblauch et al., 1997). However, the exact genetic mechanism of the disease is poorly understood.","abstract_has_math":false,"creators":["Gao, Chuan"],"institution":"Wake Forest University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2017,"date_issued":"2017","date_published":"2017","updated_at":"2026-07-27T22:02:05Z","subjects":["Cardiometabolic syndrome"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10339/82160","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Gao, Chuan"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2017-06-15T08:35:29Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2019-06-14T08:30:13Z"]},{"key":"dc:date.issued","label":"Date","values":["2017"]},{"key":"dc:publisher","label":"Institution","values":["Wake Forest University"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Cardiometabolic syndrome"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10339/82160"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Cardiometabolic syndrome (CMS) is a clustering of interrelated risk factors (central obesity, hyperglycemia, hypertension, insulin resistance, and dyslipoproteinemia) that promotes the development of atherosclerotic vascular disease and type 2 diabetes. It was recognized as a disease entity by the American Society of Endocrinology, National Cholesterol Education Program (NCEP), and World Health Organization in 2003 (Castro, El-Atat, McFarlane, Aneja, & Sowers, 2003). Previous genetic studies with monozygotic and dizygotic twin pairs suggested a strongly heritable pattern for CMS risk factors, i.e. it is estimated that circulating lipid heritability ranges from 0.58 to 0.66 (h2HDL=0.61, h2LDL=0.59, h2TC=0.58, h2TG=0.66) (Knoblauch et al., 1997). However, the exact genetic mechanism of the disease is poorly understood."]},{"key":"dc:title","label":"Title","values":["INVESTIGATION OF THE GENETIC ARCHITECTURE OF CARDIOMETABOLIC DISEASE"]}]}],"canonical_facts":{"dc:creator":["Gao, Chuan"],"dc:date.accessioned":["2017-06-15T08:35:29Z"],"dc:date.available":["2019-06-14T08:30:13Z"],"dc:date.issued":["2017"],"dc:description.abstract":["Cardiometabolic syndrome (CMS) is a clustering of interrelated risk factors (central obesity, hyperglycemia, hypertension, insulin resistance, and dyslipoproteinemia) that promotes the development of atherosclerotic vascular disease and type 2 diabetes. It was recognized as a disease entity by the American Society of Endocrinology, National Cholesterol Education Program (NCEP), and World Health Organization in 2003 (Castro, El-Atat, McFarlane, Aneja, & Sowers, 2003). Previous genetic studies with monozygotic and dizygotic twin pairs suggested a strongly heritable pattern for CMS risk factors, i.e. it is estimated that circulating lipid heritability ranges from 0.58 to 0.66 (h2HDL=0.61, h2LDL=0.59, h2TC=0.58, h2TG=0.66) (Knoblauch et al., 1997). However, the exact genetic mechanism of the disease is poorly understood."],"dc:identifier.uri":["http://hdl.handle.net/10339/82160"],"dc:language.iso":["en"],"dc:publisher":["Wake Forest University"],"dc:subject":["Cardiometabolic syndrome"],"dc:title":["INVESTIGATION OF THE GENETIC ARCHITECTURE OF CARDIOMETABOLIC DISEASE"],"dc:type":["Dissertation"]},"updated_at":"2026-07-27T22:02:05Z"}